Subtype-specific response to bevacizumab is reflected in the metabolome and transcriptome of breast cancer xenografts

► Response to bevacizumab was investigated in xenograft models of two common breast cancer subtypes. ► Combination treatment with bevacizumab had the strongest growth inhibiting effect in basal-like tumors. ► Most efficient treatment accompanied with the largest magnitude of gene expression changes. ► Hypoxia was increased with bevacizumab treatment in basal-like tumors. ► Levels of glycerophosphocholine showed opposite patterns of response in the two models.